Literature DB >> 309473

Interaction of platelet membrane receptors with von Willebrand factor, ristocetin, and the Fc region of immunoglobulin G.

A Moore, G D Ross, R L Nachman.   

Abstract

The agglutination of human platelets by ristocetin and von Willebrand factor was inhibited by aggregated immunoglobulin (Ig)G and by Fc fragments of IgG, but not by Fab, F(ab')(2) or pFc fragments of IgG. Because this inhibition occurred with formalin-fixed platelets as well as with normal platelets, a generalized aggregation of fluid membrane components by Fc fragments was not responsible for this inhibition of ristocetin and von Willebrand factor-induced agglutination. Reciprocal inhibition of platelet Fc receptors was produced by prior incubation of platelets with von Willebrand factor and ristocetin. Sucrose density gradient ultracentrifugation studies demonstrated that aggregated IgG did not form fluid-phase complexes with von Willebrand factor and ristocetin. Furthermore, passage of von Willebrand factor and ristocetin through a column of immobilized heat-aggregated IgG did not alter platelet agglutinating activity which indicates that aggregated IgG did not inactivate von Willebrand factor or ristocetin. Thus, it was likely that the IgG-mediated interference with platelet agglutination by ristocetin and von Willebrand factor did not occur in the fluid phase but at the platelet surface. These studies suggest that the platelet membrane Fc receptor may be either a part of, or sterically related to, the membrane glycoprotein I complex that interacts with von Willebrand factor, and that occupation of one of these surface components blocks the availability of the other.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 309473      PMCID: PMC371865          DOI: 10.1172/JCI109210

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  On the characterization of acquired inhibitors to ristocetin induced platelet aggregation found in patients with von Willebrand's disease.

Authors:  N Egberg; M Blombäck
Journal:  Thromb Res       Date:  1976-11       Impact factor: 3.944

2.  Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds.

Authors:  A NISONOFF; F C WISSLER; L N LIPMAN; D L WOERNLEY
Journal:  Arch Biochem Biophys       Date:  1960-08       Impact factor: 4.013

3.  The hydrolysis of rabbit y-globulin and antibodies with crystalline papain.

Authors:  R R PORTER
Journal:  Biochem J       Date:  1959-09       Impact factor: 3.857

4.  On the interaction between ristocetin and the ristocetin cofactor (RCOF).

Authors:  M Floyd; W Burns; D Green
Journal:  Thromb Res       Date:  1977-06       Impact factor: 3.944

5.  Binding of factor VIII to platelets in the presence of ristocetin.

Authors:  M B Zucker; S J Kim; J McPherson; R A Grant
Journal:  Br J Haematol       Date:  1977-04       Impact factor: 6.998

6.  A comparative study of the effect of modification of the surface of human platelets on the receptors for aggregated immunoglobulins and for ristocentin-von Willebrand factor.

Authors:  S L Pfueller; C S Jenkins; E F Lüscher
Journal:  Biochim Biophys Acta       Date:  1977-03-17

7.  The effects of ristocetin and von Willebrand factor on platelet electrophoretic mobility.

Authors:  B S Coller
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

8.  Studies on the mechanism of ristocetin-induced platelet agglutination. Effects of structural modification of ristocetin and vancomycin.

Authors:  B S Coller; H R Gralnick
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

9.  Immunoinhibition of ristocetin-induced platelet aggregation.

Authors:  R L Nachman; E A Jaffe; B B Weksler
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

10.  Studies of the mechanism of the human platelet release reaction induced by immunologic stimuli. III. Relationship between the binding of soluble IgG aggregates to the Fc receptor and cell response in the presence and absence of plasma.

Authors:  S L Pfueller; S Weber; E F Lüscher
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

View more
  16 in total

1.  Immunohistochemical and functional studies of glycoprotein 60 (gp60) in platelets.

Authors:  S A Mohamadein; A E Ahmed; M Griffiths; G P Sandilands; N P Lucie; K Whaley
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

2.  Increased factor VIII/vWf levels in patients with reduced platelet number.

Authors:  A Casonato; F Fabris; M Boscaro; A Girolami
Journal:  Blut       Date:  1987-05

Review 3.  Interactions between cancer cells and the microvasculature: a rate-regulator for metastasis.

Authors:  L Weiss; F W Orr; K V Honn
Journal:  Clin Exp Metastasis       Date:  1989 Mar-Apr       Impact factor: 5.150

4.  Evidence that a 210,000-molecular-weight glycoprotein (GP 210) serves as a platelet Fc receptor.

Authors:  R B Stricker; P T Reyes; L Corash; M A Shuman
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

5.  Platelet surface antigens: analysis by monoclonal antibodies. I. Antibodies. I. Immunological and biochemical studies.

Authors:  S Santoso; J Lohmeyer; H Rennich; K J Clemetson; C Mueller-Eckhardt
Journal:  Blut       Date:  1984-03

6.  Carbenicillin and penicillin G inhibit platelet function in vitro by impairing the interaction of agonists with the platelet surface.

Authors:  S J Shattil; J S Bennett; M McDonough; J Turnbull
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

7.  Incorporation of intravenously injected albumin, immunoglobulin G, and fibrinogen in guinea pig megakaryocyte granules.

Authors:  P J Handagama; M A Shuman; D F Bainton
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

8.  Acquired von Willebrand's syndrome with IgM inhibitor against von Willebrand's factor.

Authors:  M Gouault-Heilmann; M D Dumont; L Intrator; C Chenal; J L Lejonc
Journal:  J Clin Pathol       Date:  1979-10       Impact factor: 3.411

Review 9.  An acquired-pseudo Bernard Soulier syndrome occurring with autoimmune chronic active hepatitis and anti-cardiolipin antibody.

Authors:  I L Beales
Journal:  Postgrad Med J       Date:  1994-04       Impact factor: 2.401

10.  Inhibition of platelet-aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G.

Authors:  E C Lian; P T Mui; F A Siddiqui; A Y Chiu; L L Chiu
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.